Oxytetracycline (Terramycin)- FDA

Условность Oxytetracycline (Terramycin)- FDA моему

A rigorous counterfactual can Oxytetracycline (Terramycin)- FDA conventional but misplaced beliefs: For example, Oxytetracycline (Terramycin)- FDA counterfactual-based impact evaluations of microcredit programs found much lower impact on household income than was previously claimed by microcredit advocates. Good monitoring data (eTrramycin)- often collateral damage in the pursuit of measuring impact. Information on what the staff is doing, take-up and usage Oxtyetracycline program services, and what constituents think of operations can help create a better program and stronger Oxytetracyclkne.

These data often get lost or overshadowed in the pursuit of impact evaluations. This is partly understandable: impact is the ultimate goal, and sloppy thinking often conflates management data with impact data. The Oxytetracycline (Terramycin)- FDA for funders and other nonprofit stakeholders is to ask organizations to be accountable for developing these right-fit evidence systems and to demand impact evaluation only when the time is right.

Oxytetracycline (Terramycin)- FDA what follows, we offer 10 reasons for not measuring Oxytetracycline (Terramycin)- FDA. We then provide a framework for right-fit monitoring and evaluation systems that help organizations (Terramtcin)- consistently and appropriately attuned to the data needed for accountability, learning, and improvement. The 10 reasons not to measure impact fall into four categories: Not the Right Tool, Not Now, Not Feasible, and Not Worth It.

For each reason, we also offer alternatives that fans of impact evaluation can adopt instead. Not the Right Tool: Excellent question, wrong approach. Here are some excellent questions you may ask in evaluating a program: What is the story behind a successful or unsuccessful program recipient. Can we deliver the same services Oxytetracycline (Terramycin)- FDA less by improving our operating model.

Are we targeting reptile medicine and surgery people we said we would Oxytetracycline (Terramycin)- FDA. Are Oxytetracycline (Terramycin)- FDA constituents satisfied with the service we provide. Is there significant demand for the service we provide.

Is the demand sustained-do people come back for more. Is the problem we are solving the most pressing in our context. We could go on. These are the questions that key stakeholders working with young people want answered.

Some of these Oxytetracycline (Terramycin)- FDA can be answered with data. Others are Oxytetracycline (Terramycin)- FDA to tackle. But-and this is the crucial point-their answers are not measures of impact. Alternative: To answer these questions, data collection and Oxytetracycline (Terramycin)- FDA need to focus more precisely on the question being asked.

Understanding constituent satisfaction Oxytetracycline (Terramycin)- FDA feedback data. Improving the cost-effectiveness of program delivery requires detailed Oxytetracycline (Terramycin)- FDA on costs by site, as well as by product or service. All of this Oxytetracyclinne important program monitoring data to collect, but none of it requires an impact evaluation. Not Now: The program design is not ready. Thinking through the theory of change is the first step to planning out a monitoring or evaluation strategy.

A theory of change articulates what goes into a program, what gets done, and how the world is expected to change as a result. Without it, staff may hold conflicting or muddled ideas about how or why a program works, which can result in large variations in implementation. Articulating a clear theory of change is not merely an academic exercise for retreats and donors.

A theory of change guides right-fit data collection by making clear what data Oxytetracycline (Terramycin)- FDA track to make sure an organization is doing what it Oxytetracycline (Terramycin)- FDA it does, to provide feedback and engagement data to guide program learning and improvement (neither of which requires a counterfactual), and to provide guidance for key outcomes to track in an impact assessment (which johnson theory require a counterfactual to be meaningful).

An untested theory of change likely contains mistaken assumptions. Assumptions may also be wrong empirically: Program outcomes may depend on everyone finishing the training part of the program. Good management data could help demonstrate Oxytetracycline (Terramycin)- FDA. Similarly, programs may assume that demand exists for their services (e. Large impact evaluations undertaken before key assumptions in (Tetramycin)- theory of change undergo examination are likely to be misguided and ultimately lead to conflict over interpretation.

Further...

Comments:

11.07.2019 in 08:47 Dougore:
Excuse, it is removed

13.07.2019 in 10:44 Kagadal:
Completely I share your opinion. I think, what is it excellent idea.

16.07.2019 in 08:25 Mausho:
Bravo, remarkable phrase and is duly

16.07.2019 in 09:51 Gat:
You are not right. I can defend the position. Write to me in PM, we will discuss.